Abstract: Obj ective To observe the clinical effect of edaravone on treatment of patients with acute cerebral infarction (ACI)and its influence on serum superoxide dismutase (SOD)and malondialdehyde (MDA).Methods A total of 64 ACI patients were randomly divided into control group (31 cases)treated with basic medicines and treatment group (33 cases)added with with edar-avone.Clinical efficacy,neurological function deficit improvement rate,American National Insti-tutes of Health Stroke Scale (NIHSS)and Barthel index (BI)as well as serum SOD and MDA level changes in both groups were observed.Results 14 d after treatment,the clinical efficacy in treat-ment group was 84.85%,significantly higher than the 61.29% in control group (P<0.01). NIHSS and Barthel scores were better after treatment than those before (P<0.01),and differences between two groups were also significant (P<0 .05 ).After treatment,SOD level was higher in treatment group (P<0 .0 1 )and lower in control group than those before treatment (P<0 .0 1 ), whereas MDA level was lower in treatment group (P<0 .0 1 )and higher in control group than those before treatment (P<0 .05 ).Additionally,there had no severe adverse responses in both groups. Conclusion On the basis of basic treatment,the application of edaravone has favorable clinical effi-cacy and safety in the treatment of ACI .